



**HAL**  
open science

## Lung transplantation in HIV-positive patients: a European retrospective cohort study

Claire Rouzaud, Cristina Berastegui, Clément Picard, Robin Vos, Laurent Savale, Xavier Demant, Alessandro Bertani, Erik Verschuuren, Peter Jaksch, Anna Reed, et al.

### ► To cite this version:

Claire Rouzaud, Cristina Berastegui, Clément Picard, Robin Vos, Laurent Savale, et al.. Lung transplantation in HIV-positive patients: a European retrospective cohort study. *European Respiratory Journal*, 2022, 60 (1), pp.2200189. 10.1183/13993003.00189-2022 . hal-04521639

**HAL Id: hal-04521639**

**<https://hal.science/hal-04521639v1>**

Submitted on 13 Nov 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



## Early View

Research letter

### **Lung transplantation in HIV-positive patients: a european retrospective cohort study**

Claire Rouzaud, Cristina Berastegui, Clément Picard, Robin Vos, Laurent Savale, Xavier Demant, Alessandro Bertani, Erik Verschuuren, Peter Jaksch, Anna Reed, Letizia Corinna Morlacchi, Martine Reynaud-Gaubert, Olivier Lortholary, Elie Fadel, Marc Humbert, Jens Gottlieb, Jérôme Le Pavec

Please cite this article as: Rouzaud C, Berastegui C, Picard C, *et al.* Lung transplantation in HIV-positive patients: a european retrospective cohort study. *Eur Respir J* 2022; in press (<https://doi.org/10.1183/13993003.00189-2022>).

This manuscript has recently been accepted for publication in the *European Respiratory Journal*. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online.

Copyright ©The authors 2022. For reproduction rights and permissions contact [permissions@ersnet.org](mailto:permissions@ersnet.org)

# **Lung Transplantation in HIV-Positive Patients: A European Retrospective Cohort**

## **Study**

Claire Rouzaud, MD<sup>1</sup>; Cristina Berastegui, MD<sup>2</sup>; Clément Picard, MD<sup>3</sup>; Robin Vos, MD<sup>4,5</sup>;  
Laurent Savale, MD<sup>6,7,8</sup>; Xavier Demant, MD<sup>9</sup>; Alessandro Bertani, MD<sup>10</sup>; Erik Verschuuren,  
MD<sup>9</sup>; Peter Jaksch, MD<sup>10</sup>; Anna Reed, MD<sup>11,12</sup>; Letizia Corinna Morlacchi, MD<sup>13</sup>; Martine  
Reynaud-Gaubert, MD<sup>14</sup>; Olivier Lortholary, MD<sup>1</sup>; Elie Fadel, MD<sup>6,7,15</sup> Marc Humbert,  
MD<sup>6,7,8</sup>; Jens Gottlieb<sup>¥</sup>, MD<sup>16</sup>; Jérôme Le Pavec<sup>¥</sup>, MD<sup>6,7,17</sup>

1: Assistance Publique Hôpitaux de Paris, Department of Infectious and Tropical Diseases, Hôpital Necker-Enfants Malades, F-75015, Paris, France; SAMU Social de Paris, 35 avenue Courteline, 75012, Paris, France

2: Department of Respiratory Medicine, Lung Transplant Unit, Hospital Universitario Vall d'Hebron, Barcelona, Spain

3: Service de Transplantation Pulmonaire et Centre de Compétence de la Mucoviscidose, Foch Hospital, Suresnes, France

4: Department of Respiratory Diseases, University Hospitals Leuven - Gasthuisberg Campus, Leuven, Belgium

5: Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium

6: Université Paris-Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France

7: INSERM UMR\_S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France

8: Assistance Publique Hôpitaux de Paris, Service de Pneumologie et Soins Intensifs Respiratoires, Hôpital Bicêtre, Le Kremlin Bicêtre, France

9: Department of Respiratory Medicine, Haut-Lévêque Hospital, Bordeaux University, Pessac, France

10: Department of Thoracic Surgery, IRCCS-ISMETT (Mediterranean Institute for Transplantation and Advanced Specialized Therapies), 90127 Palermo, Italy

9: University Medical Center Groningen, Respiratory Diseases and Lung Transplantation, Groningen, The Netherlands

10: Division of Thoracic Surgery, Medical University of Vienna, Vienna, Austria

11: Cardiothoracic Transplant Unit, Royal Brompton & Harefield Hospitals, London SW3 6NP, UK

12: Imperial College London, London SW3 6NP, UK

13: Respiratory Unit and Adult Cystic Fibrosis Center, Internal Medicine Department, Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, Milan, Italy

14: Service de Pneumologie et Équipe de Transplantation Pulmonaire, Centre Hospitalo-Universitaire Nord, Assistance Publique-Hôpitaux de Marseille, Aix-Marseille Université, France

15: Service de Chirurgie Thoracique et Transplantation Pulmonaire, Hôpital Marie Lannelogue, Groupe Hospitalier Paris-Saint Joseph, Le Plessis-Robinson, France

16: Department of Respiratory Medicine, Hannover, Germany

17: Service de Pneumologie et Transplantation Pulmonaire, Hôpital Marie Lannelogue, Groupe Hospitalier Paris-Saint Joseph, Le Plessis-Robinson, France

‡: contributed equally to this work

**Corresponding author:** Dr Jérôme Le Pavec, Service de Pneumologie et Transplantation Pulmonaire, Hôpital Marie Lannelongue, Groupe Hospitalier Paris-Saint Joseph, 133 avenue de la Résistance, 92350 Le Plessis-Robinson, France

Tel: +33 140 942 430; Fax: +33 140 948 682; E-mail: [lepavec@gmail.com](mailto:lepavec@gmail.com)

**Funding information**

No funding was received for this study.

**Word count text:** 1150

Steady progress in antiretroviral therapy, with the introduction of new medications and the earlier institution of more aggressive treatment regimens, has markedly improved the outcomes of human immunodeficiency virus (HIV) infection [1]. The longer life expectancy provided by optimal management is associated with an increased risk of eventually developing chronic medical conditions, including lung diseases and pulmonary arterial hypertension, many of which can be treated but not cured [2,3].

Transplantation of organs from HIV-positive donors was a federal crime in the US until the HIV Organ Policy Equity (HOPE) Act was signed into law in 2013 to allow transplantation between HIV-positive individuals. In Europe, legislation varies across countries, but transplantation from HIV-positive donors to HIV-recipients is usually allowed [4]. Nonetheless, HIV infection has often been considered to contraindicate organ transplantation [5]. Recently, improvements in the outcomes of both HIV infection and transplantation have prompted several centres to adopt a case-by-case approach to patients with controlled HIV infection. Over the last decade, acceptable outcomes have been reported in 11 LTx recipients and one heart-LTx recipient [6–8]. However, data on LTx in HIV-positive patients remain limited.

The objective of this multicentre retrospective study was to obtain further information on key transplantation- and HIV-related outcomes of HIV-positive patients treated with LTx. We identified 68 LTx centres in 22 European countries via the International Society for Heart and Lung Transplantation (ISHLT) registry and by personal knowledge. Each centre received a 54-item questionnaire seeking information, including outcome data, about consecutive HIV-positive patients who underwent LTx in 2007–2021. For each patient, data were recorded until 1 September 2021. Performance status was rated on the World Health Organisation scale (0, fully active; 5, death) [9]. Baseline variables were described as median [25<sup>th</sup>–75<sup>th</sup> percentiles] if continuous and as percentage if categorical and were compared by applying

Fisher's exact test or the Kruskal-Wallis test, as appropriate. Median follow-up was 25 months and the Kaplan-Meier method was applied to assess survival. Our institutional review board (*Groupe Hospitalier Paris-Saint Joseph*) and the local ethics committees for each participating centre approved the study protocol (*Groupe Éthique Recherche Médicale*, IRB 00012157). The requirement for informed consent was waived in compliance with legislation about retrospective studies of anonymised data.

Among the 68 centres, 25 returned the completed questionnaire, allowing the identification of 22 HIV-positive LTx recipients. The viral load was negative in all patients at listing and did not change significantly after transplantation. At transplantation, no patient was receiving protease-inhibitor therapy. A change in the antiretroviral regimen before LTx was deemed necessary in three (15%) patients, due to osteoporosis, renal insufficiency, and an unknown reason, respectively. Interestingly, PAH, a condition associated with HIV infection [10], was the main reason for LTx in our cohort. Median follow-up was 25 [6–52] months after transplantation. Of the eight (40%) patients with post-LTx infections requiring admission, six had bacterial pneumonia, one pulmonary invasive aspergillosis, and one gastroenteritis. Seven patients received induction therapy, consisting in anti-thymocyte globulin in two and basiliximab in five. During follow-up, acute cellular rejection, antibody-mediated rejection, and chronic allograft dysfunction developed in 7/19 (37%), 2/19 (11%), and 5/19 (26%) patients, respectively. None of the patients with rejection episodes had received induction therapy. The malignancies diagnosed during follow-up consisted of one case each of colonic adenocarcinoma, Kaposi's sarcoma, and squamous-cell carcinoma of the skin. The estimated glomerular filtration rate decreased significantly over the first post-transplantation year. Four patients died during follow-up, including two within the first three post-operative months, from haemorrhagic shock and grade-3 primary graft dysfunction,

respectively. Post-transplant survival rates after 1, 3, and 5 years were 79%, 79%, and 79%, respectively. At last follow-up, 13 (59%) patients were fully active and independent.

To date, this is the largest case-series of LTx in HIV-positive recipients. The good outcomes in highly-selected patients validate and expand upon previous reports. A multicentre study by Koval et al.[6] included 29 HIV-positive patients who underwent heart (n=21), lung (n=7), or heart-lung (n=1) transplantation in 2000–2016. In the eight LTx recipients, 1-, 3-, and 5-year survival rates were 86%, 80%, and 75%, i.e., similar to those in the overall LTx population in the ISHLT registry.

The 1-year acute cellular rejection rate in HIV-positive patients was 37%, whereas the rejection rate in an overall population of patients who underwent LTx in 2005–2018 was 26% [11]. Nonetheless, these early rejections did not translate into decreased graft survival during the first five years [11]. Higher rejection rates in HIV-positive recipients have been reported in several studies [5,11,12]. The impact of HIV-associated immune activation has been under-recognised and remains insufficiently understood, notably in the transplant arena. Cautious immunosuppression aimed at avoiding an unacceptable risk of infection has long been blamed for the higher rejection rates in HIV-positive recipients. Thus, according to the Scientific Registry of Transplant Recipients, HIV-positive kidney and heart recipients were less likely to undergo induction immunosuppression and to receive anti-thymocyte globulin or alemtuzumab [5,13]. In our cohort, only 32% of patients received induction therapy. In contrast, the proportion of ISHLT-registry patients given induction therapy has risen steadily, reaching 80% in 2017 [11].

Drug interactions, chiefly involving protease inhibitors, may affect maintenance immunosuppressive therapy, thereby contributing to the higher rejection rate in HIV-positive patients [15]. Of note, three (15%) of our patients required a change in their antiretroviral regimen before LTx, but in none was the change motivated by concern about interactions with



calcineurin inhibitors. Overall, the main regimen at LTx was a combination of nucleoside reverse transcriptase inhibitors and integrase inhibitors, without pharmacologic boosters.

HIV infection remained controlled in all the study patients, with stable CD4<sup>+</sup> T-cell counts and no instances of viremia or AIDS-related events. The 40% frequency of infectious episodes after LTx was not different from that reported in the overall LTx population [16]. Last, although four patients received tenofovir disoproxil, a drug potentially associated with renal tubulopathy, the significant decrease in the estimated glomerular filtration rate during the first post-transplant year was consistent with results in HIV-negative LTx recipients [17]. Of note, this finding suggests good patient selection and may also be related to the more cautious approach to immunosuppression.

The general applicability of our findings deserves discussion. Only 25 of the 68 invited centres returned the completed questionnaire, and we cannot rule out selection bias towards patients with better outcomes. Although this is the largest study of LTx in HIV-positive patients, the sample size remains small, limiting the ability to draw definitive conclusions. As the population with well-controlled HIV infection grows, so, too, will the number of HIV-positive LTx candidates who might be included in prospective studies.

In summary, LTx is a successful treatment modality in selected HIV-positive patients with advanced lung disease. Until further data become available, the high rejection rates in HIV-positive LTx recipients support the use of immunosuppressive regimens similar to those given to HIV-negative patients. Information from prospective studies is needed to optimise the care of this specific population.

## References

1. Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. *Lancet* 2013; 382: 1525–1533.
2. A cross-sectional, population-based study measuring comorbidity among people living with HIV in Ontario - PubMed [Internet]. [cited 2021 Dec 26]. Available from: <https://pubmed-ncbi-nlm-nih-gov.proxy.insermbiblio.inist.fr/24524286/>.
3. Ingle SM, May MT, Gill MJ, Mugavero MJ, Lewden C, Abgrall S, Fätkenheuer G, Reiss P, Saag MS, Manzardo C, Grabar S, Bruyand M, Moore D, Mocroft A, Sterling TR, D'Arminio Monforte A, Hernando V, Teira R, Guest J, Cavassini M, Crane HM, Sterne JAC, Antiretroviral Therapy Cohort Collaboration. Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients. *Clin Infect Dis* 2014; 59: 287–297.
4. Werbel WA, Durand CM. Solid Organ Transplantation in HIV-Infected Recipients: History, Progress, and Frontiers. *Curr HIV/AIDS Rep* 2019; 16: 191–203.
5. Leard LE, Holm AM, Valapour M, Glanville AR, Attawar S, Aversa M, Campos SV, Christon LM, Cypel M, Dellgren G, Hartwig MG, Kapnadak SG, Kolaitis NA, Kotloff RM, Patterson CM, Shlobin OA, Smith PJ, Solé A, Solomon M, Weill D, Wijnsenbeek MS, Willemsse BWM, Arcasoy SM, Ramos KJ. Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. *J Heart Lung Transplant* 2021; : S1053-2498(21)02407-4.
6. Koval CE, Farr M, Krisl J, Haidar G, Pereira MR, Shrestha N, Malinis MF, Mueller NJ, Hannan MM, Grossi P, Huprikar S. Heart or lung transplant outcomes in HIV-infected recipients. *J Heart Lung Transplant* 2019; 38: 1296–1305.
7. Bertani A, Grossi P, Vitulo P, D'Ancona G, Arcadipane A, Nanni Costa A, Gridelli B. Successful lung transplantation in an HIV- and HBV-positive patient with cystic fibrosis. *Am J Transplant* 2009; 9: 2190–2196.
8. Kern RM, Seethamraju H, Blanc PD, Sinha N, Loebe M, Golden J, Kukreja J, Scheinin S, Hays S, Kleinhenz ME, Leard L, Hoopes C, Singer JP. The feasibility of lung transplantation in HIV-seropositive patients. *Ann Am Thorac Soc* 2014; 11: 882–889.
9. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol* 1982; 5: 649–655.
10. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M,

Williams PG, Souza R. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. *Eur Respir J* [Internet] 2019 [cited 2020 Apr 20]; 53 Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6351336/>.

11. Chambers DC, Cherikh WS, Harhay MO, Hayes D, Hsich E, Khush KK, Meiser B, Potena L, Rossano JW, Toll AE, Singh TP, Sadavarte A, Zuckermann A, Stehlik J. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart–lung transplantation Report—2019; Focus theme: Donor and recipient size match. *The Journal of Heart and Lung Transplantation* 2019; 38: 1042–1055.
12. Locke JE, James NT, Mannon RB, Mehta SG, Pappas PG, Baddley JW, Desai NM, Montgomery RA, Segev DL. Immunosuppression regimen and the risk of acute rejection in HIV-infected kidney transplant recipients. *Transplantation* 2014; 97: 446–450.
13. Malat GE, Ranganna KM, Sikalas N, Liu L, Jindal RM, Doyle A. High frequency of rejections in HIV-positive recipients of kidney transplantation: a single center prospective trial. *Transplantation* 2012; 94: 1020–1024.
14. Kucirka LM, Durand CM, Bae S, Avery RK, Locke JE, Orandi BJ, McAdams-DeMarco M, Grams ME, Segev DL. Induction Immunosuppression and Clinical Outcomes in Kidney Transplant Recipients Infected With Human Immunodeficiency Virus. *Am J Transplant* 2016; 16: 2368–2376.
15. Sawinski D, Shelton BA, Mehta S, Reed RD, MacLennan PA, Gustafson S, Segev DL, Locke JE. Impact of Protease Inhibitor-Based Anti-Retroviral Therapy on Outcomes for HIV+ Kidney Transplant Recipients. *Am J Transplant* 2017; 17: 3114–3122.
16. Palacio F, Reyes LF, Levine DJ, Sanchez JF, Angel LF, Fernandez JF, Levine SM, Rello J, Abedi A, Restrepo MI. Understanding the Concept of Health Care-Associated Pneumonia in Lung Transplant Recipients. *Chest* 2015; 148: 516–522.
17. Hellemons ME, Bakker SJL, Postmus D, Verschuuren EAM, Erasmus ME, Navis G, van der Bij W. Incidence of impaired renal function after lung transplantation. *J Heart Lung Transplant* 2012; 31: 238–243.

**Table 1: Main features of the 22 study patients**

	Overall n = 22	p value*
<b>Baseline characteristics</b>		
Male, n (%)	14 (64)	
Recipient age (y), med [IQR]	49 [45 - 55]	
Caucasian, n (%)	13 (59)	
Transplantation indications, PAH / Fibrosis / COPD / Cystic Fibrosis / Other, n(%)	7 (32) / 5 (23) / 4 (18) / 3 (14) / 3 (14)	
Transplantation procedure, double / single, n(%)	20 (91) / 2 (9)	
Induction therapy, n(%)	7 (32)	
<b>HIV characteristics</b>		
CD4 T cell count before / after transplantation (cell/mm <sup>3</sup> ), med [IQR] *	514 [351 – 670] / 484 [229 – 622]	0.91
RNA viral load, before / after transplantation (copies/mL), med [IQR] *	0 / 0	0.99
History of opportunistic infection, n(%)	2 (9%)	
History of acquired immunodeficiency syndrome status, n(%)	2 (9%)	
Hepatitis B surface antigen positivity, n(%)	6 (27)	
Hepatitis virus C antibody positivity, n(%)	4 (18)	
Antiretroviral therapy regimen at transplantation, n(%)		
Nucleoside Reverse Transcriptase Inhibitors / integrase inhibitors	13 (62)	
Non nucleoside Reverse Transcriptase Inhibitors / integrase inhibitors	4 (19)	
Nucleoside Reverse Transcriptase Inhibitors / Non nucleoside Reverse Transcriptase Inhibitors	3 (14)	
Integrase inhibitors	1 (5)	
Antiretroviral therapy change before transplantation, n(%) , n = 20	3 (15)	
<b>Post operative outcome</b>		
Infections requiring hospitalization during 1 <sup>st</sup> year, n(%) , n = 20	8 (40)	
Acute cellular rejection, n(%) , n = 19	7 (37)	
Antibody mediated rejection, n(%) , n = 19	2 (11)	
Chronic lung allograft dysfunction at last follow-up, n (%) , n = 19	5 (26)	
Malignancy, n(%) , n = 21	3 (14)	
Estimated glomerular filtration rate (mL/min/1.73 m <sup>2</sup> ), before / after transplantation, med [IQR]***	90 [80 – 111] / 73 [53 – 90]	0.02
<b>Status at last news</b>		
World Health Organization scale 0 / 1 / 2 / 3, n(%)	9 (41) / 4 (18) / 4 (18) / 5 (23)	
Immunosuppressive regimen at last news, n(%)		
Tacrolimus + steroids + MMF	15 (67)	
Cyclosporine + steroids + MMF	2 (10)	
Tacrolimus + steroids + everolimus	2 (10)	
Other	3 (13)	

LTX, lung transplantation; MMF, mycophenolate mofetil

\*: evaluated at last follow-up

\*\*: The two patients with a history of opportunistic infection are the same as the two with acquired immunodeficiency syndrome.

\*\*\*: evaluated 1 year after transplantation

## **ACKNOWLEDGEMENTS**

### **Guarantor statement**

J Le Pavec takes responsibility for the content of the manuscript, including the data and analysis.

### **Author contributions**

1: Conception and design; 2: Acquisition of data; 3: Analysis and interpretation of data; 4:

Article drafting and revising

CR: 1, 2, 3, 4

CB: 2, 3, 4

CP: 2, 3, 4

RV: 1,2, 4

LS: 2,4

XD: 2, 3, 4

AB: 2, 3, 4

EV: 2, 3, 4

PJ: 2, 3, 4

AR: 2, 3, 4

LCM: 2, 3, 4

MRG: 2, 3, 4

OL: 4

EL: 4

MH: 4

JG: 1, 2, 3, 4

JLP: 1, 2, 3, 4

**Conflict of interest**

None of the authors has any conflicts of interest to disclose.